These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38395973)

  • 21. Performances and variability of CT radiomics for the prediction of microvascular invasion and survival in patients with HCC: a matter of chance or standardisation?
    Cannella R; Santinha J; Bèaufrere A; Ronot M; Sartoris R; Cauchy F; Bouattour M; Matos C; Papanikolaou N; Vilgrain V; Dioguardi Burgio M
    Eur Radiol; 2023 Nov; 33(11):7618-7628. PubMed ID: 37338558
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Contrast-enhanced CT radiomics for prediction of recurrence-free survival in gallbladder carcinoma after surgical resection.
    Xiang F; Liang X; Yang L; Liu X; Yan S
    Eur Radiol; 2022 Oct; 32(10):7087-7097. PubMed ID: 35612664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Accurate non-invasive grading of nonfunctional pancreatic neuroendocrine tumors with a CT derived radiomics signature.
    Javed AA; Zhu Z; Kinny-Köster B; Habib JR; Kawamoto S; Hruban RH; Fishman EK; Wolfgang CL; He J; Chu LC
    Diagn Interv Imaging; 2024 Jan; 105(1):33-39. PubMed ID: 37598013
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preoperative Radiomics Nomogram Based on CT Image Predicts Recurrence-Free Survival After Surgical Resection of Hepatocellular Carcinoma.
    Li Z; Yu J; Li Y; Liu Y; Zhang M; Yang H; Du Y
    Acad Radiol; 2023 Aug; 30(8):1531-1543. PubMed ID: 36653278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk factors for short recurrence-free survival after resection of pancreatic neuroendocrine tumor (PanNET) liver metastases: which patients should undergo resection?
    Masui T; Nagai K; Anazawa T; Kasai Y; Sato A; Nakano K; Uchida Y; Yogo A; Kawaguchi Y; Takaori K; Uemoto S
    Scand J Gastroenterol; 2020 Apr; 55(4):479-484. PubMed ID: 32223573
    [No Abstract]   [Full Text] [Related]  

  • 26. Radiomics signature for prediction of long-term survival and recurrence patterns in patients with gastric cancer after radical gastrectomy: A multicenter study.
    Huang JM; Zhuang LP; Wang HG; Zhong LY; Xue SJ; Tian FX; Lin HY
    Saudi J Gastroenterol; 2023; 29(1):21-30. PubMed ID: 36588364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CT Radiogenomic Characterization of the Alternative Lengthening of Telomeres Phenotype in Pancreatic Neuroendocrine Tumors.
    McGovern JM; Singhi AD; Borhani AA; Furlan A; McGrath KM; Zeh HJ; Bahary N; Dasyam AK
    AJR Am J Roentgenol; 2018 Nov; 211(5):1020-1025. PubMed ID: 30160983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiparametric MRI-Based Radiomic Signature for Preoperative Evaluation of Overall Survival in Intrahepatic Cholangiocarcinoma After Partial Hepatectomy.
    Yang Y; Zou X; Zhou W; Yuan G; Hu D; Kuang D; Shen Y; Xie Q; Zhang Q; Hu X; Li Z
    J Magn Reson Imaging; 2022 Sep; 56(3):739-751. PubMed ID: 35049076
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Surgery Versus Surveillance for Well-Differentiated, Nonfunctional Pancreatic Neuroendocrine Tumors: An 11-Year Analysis of the National Cancer Database.
    Assi HA; Mukherjee S; Kunz PL; Machiorlatti M; Vesely S; Pareek V; Hatoum H
    Oncologist; 2020 Feb; 25(2):e276-e283. PubMed ID: 32043766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incremental value of PET primary lesion-based radiomics signature to conventional metabolic parameters and traditional risk factors for preoperative prediction of lymph node metastases in gastric cancer.
    Xue XQ; Yu WJ; Shao XL; Wang YT
    Abdom Radiol (NY); 2023 Feb; 48(2):510-518. PubMed ID: 36418614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Special issue "The advance of solid tumor research in China": Prediction of Sunitinib efficacy using computed tomography in patients with pancreatic neuroendocrine tumors.
    Chen L; Wang W; Jin K; Yuan B; Tan H; Sun J; Guo Y; Luo Y; Feng ST; Yu X; Chen MH; Chen J
    Int J Cancer; 2023 Jan; 152(1):90-99. PubMed ID: 36111424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinicopathological characteristics and risk factors for recurrence of well-differentiated pancreatic neuroendocrine tumors after radical surgery: a case-control study.
    Zhang P; Li YL; Qiu XD; Luo J; Shi YF; Sun YL; Su F; Qi ZR; Tan HY
    World J Surg Oncol; 2019 Apr; 17(1):66. PubMed ID: 30975157
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radiologic tumor border can further stratify prognosis in patients with pancreatic neuroendocrine tumor.
    Ahn B; Park HJ; Kim HJ; Hong SM
    Pancreatology; 2024 Aug; 24(5):753-763. PubMed ID: 38796309
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radical Resection in Entero-Pancreatic Neuroendocrine Tumors: Recurrence-Free Survival Rate and Definition of a Risk Score for Recurrence.
    Merola E; Pascher A; Rinke A; Bartsch DK; Zerbi A; Nappo G; Carnaghi C; Ciola M; McNamara MG; Zandee W; Bertani E; Marcucci S; Modica R; Grützmann R; Fazio N; de Herder W; Valle JW; Gress TM; Fave GD; de Pretis G; Perren A; Wiedenmann B; Pavel ME
    Ann Surg Oncol; 2022 Sep; 29(9):5568-5577. PubMed ID: 35583694
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radiomic Features at Contrast-enhanced CT Predict Recurrence in Early Stage Hepatocellular Carcinoma: A Multi-Institutional Study.
    Ji GW; Zhu FP; Xu Q; Wang K; Wu MY; Tang WW; Li XC; Wang XH
    Radiology; 2020 Mar; 294(3):568-579. PubMed ID: 31934830
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of Recurrence and Survival in Patients With Surgically Resected Pancreatic Neuroendocrine Tumors.
    Rosenblum RE; Harris CK; Baeg KJ; Starr JA; Brais LK; Stashek KM; Ward SC; Katona BW; Clancy TE; Wisnivesky JP; Kulke MH; Metz DC; Kim MK; Chan JA
    Pancreas; 2020 Feb; 49(2):249-254. PubMed ID: 32011530
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CT-Based Radiomics Score for Distinguishing Between Grade 1 and Grade 2 Nonfunctioning Pancreatic Neuroendocrine Tumors.
    Bian Y; Jiang H; Ma C; Wang L; Zheng J; Jin G; Lu J
    AJR Am J Roentgenol; 2020 Oct; 215(4):852-863. PubMed ID: 32755201
    [No Abstract]   [Full Text] [Related]  

  • 38. A Prognostic Scoring System for the Prediction of Metastatic Recurrence Following Curative Resection of Pancreatic Neuroendocrine Tumors.
    Sho S; Court CM; Winograd P; Toste PA; Pisegna JR; Lewis M; Donahue TR; Hines OJ; Reber HA; Dawson DW; Tomlinson JS
    J Gastrointest Surg; 2019 Jul; 23(7):1392-1400. PubMed ID: 30353489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Defining the Role of Lymphadenectomy for Pancreatic Neuroendocrine Tumors: An Eight-Institution Study of 695 Patients from the US Neuroendocrine Tumor Study Group.
    Lopez-Aguiar AG; Zaidi MY; Beal EW; Dillhoff M; Cannon JGD; Poultsides GA; Kanji ZS; Rocha FG; Marincola Smith P; Idrees K; Beems M; Cho CS; Fisher AV; Weber SM; Krasnick BA; Fields RC; Cardona K; Maithel SK
    Ann Surg Oncol; 2019 Aug; 26(8):2517-2524. PubMed ID: 31004295
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development and Validation of a CT-Based Radiomics Nomogram for Predicting Postoperative Progression-Free Survival in Stage I-III Renal Cell Carcinoma.
    Zhang H; Yin F; Chen M; Yang L; Qi A; Cui W; Yang S; Wen G
    Front Oncol; 2021; 11():742547. PubMed ID: 35155180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.